Structural biologists have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells, dysfunctions of which have been implicated in depression, schizophrenia, Parkinson’s and Alzheimer’s diseases.